 TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 SINGLE AGENT IN PARTICIPANTS WITH SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PARTICIPANTS WITH BREAST CANCER: 